NCT04920383View on ClinicalTrials.gov

ALPN-202 With PD-1 Inhibition in Advanced Malignancies

PHASE1TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

November 8, 2022

Study Completion Date

February 28, 2023

Conditions
Advanced Solid TumorLymphoma
Interventions
DRUG

ALPN-202

Various doses

DRUG

pembrolizumab KEYTRUDA®

Varies

Trial Locations (5)

30322

Investigational Site (213), Atlanta

37203

Investigational Site (203), Nashville

49546

Investigational Site (301), Grand Rapids

78229

Investigational Site (215), San Antonio

02114

Investigational Site (212), Boston

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Alpine Immune Sciences, Inc.

INDUSTRY

NCT04920383 - ALPN-202 With PD-1 Inhibition in Advanced Malignancies | Biotech Hunter | Biotech Hunter